Home › Zydelig in Combination With Ofatumumab Improves Progression-Free...
 

Keywords :   


Zydelig in Combination With Ofatumumab Improves Progression-Free...

2015-05-31 19:33:26| Biotech - Topix.net

Phase 3 Study Results Showing 73 Percent Reduction versus Ofatumumab Alone in Risk of Disease Progression or Death to be Presented at American Society of Clinical Oncology Annual Meeting -- CHICAGO-- -- Gilead Sciences, Inc. today announced results from the Phase 3 clinical Study 119 of an investigational use of ZydeligA in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukemia . In Study 119, there was a 73 percent reduction in the risk of disease progression or death in patients receiving Zydelig in combination with ofatumumab compared to ofatumumab alone = 0.27; 95 percent CI: 0.19, 0.39; p<0.0001).

Tags: combination improves progressionfree ofatumumab

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Tropical Storm Milton Public Advisory Number 2
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 26
05.10Tropical Storm Milton Graphics
05.10Hurricane Kirk Wind Speed Probabilities Number 26
05.10Hurricane Leslie Graphics
05.10Hurricane Kirk Public Advisory Number 26
05.10Summary for Hurricane Kirk (AT2/AL122024)
More »